Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005571|
Recruitment Status : Completed
First Posted : April 26, 2000
Last Update Posted : March 4, 2008
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by:
National Institutes of Health Clinical Center (CC)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||No date given|
|Study Completion Date :||December 2001|
Pearson CM, Bohan A. The spectrum of polymyositis and dermatomyositis. Med Clin North Am. 1977 Mar;61(2):439-57. Review.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991 Nov;70(6):360-74.